celecoxib and zd 6474
celecoxib has been researched along with zd 6474 in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Ballabh, P; Braun, A; Csiszar, A; Goldman, SA; Hu, F; Lou, N; Nedergaard, M; Rivera, A; Smith, K; Ungvari, Z; Xu, H | 1 |
| Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X | 1 |
Other Studies
4 other study(ies) available for celecoxib and zd 6474
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Angiogenic inhibition reduces germinal matrix hemorrhage.
Topics: Aborted Fetus; Angiopoietin-2; Animals; Blotting, Western; Brain; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Endothelial Cells; Humans; Immunohistochemistry; Infant, Newborn; Infant, Premature; Intracranial Hemorrhages; Neovascularization, Physiologic; Piperidines; Pyrazoles; Quinazolines; Rabbits; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Phosphorylation; Piperidines; Quinazolines; Xenograft Model Antitumor Assays | 2015 |